Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Dermatology

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 146 articles:
HTML format



Single Articles


    February 2025
  1. DUNN JA, Donnelly P, Elbeltagi N, Marshall A, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2025;405:396-407.
    PubMed     Abstract available


  2. SABAT R, Alavi A, Wolk K, Wortsman X, et al
    Hidradenitis suppurativa.
    Lancet. 2025;405:420-438.
    PubMed     Abstract available


    January 2025
  3. FIORENTINO D, Mangold AR, Werth VP, Christopher-Stine L, et al
    Efficacy, safety, and target engagement of dazukibart, an IFNbeta specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Lancet. 2025;405:137-146.
    PubMed     Abstract available


    December 2024
  4. WEIDINGER S, Novak N
    Hand eczema.
    Lancet. 2024;404:2476-2486.
    PubMed     Abstract available


    November 2024
  5. CHONG DHY, Pasternak S, Taylor T, Armstrong S, et al
    Skin biopsy findings of dyskeratotic keratinocytes and vacuolar interface change in a patient with Still's disease.
    Lancet. 2024;404:e6.
    PubMed    


  6. SOMA T, Oie Y, Takayanagi H, Matsubara S, et al
    Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan.
    Lancet. 2024 Nov 7:S0140-6736(24)01764-1. doi: 10.1016/S0140-6736(24)01764.
    PubMed     Abstract available


    October 2024
  7. JAIRATH V, Acosta Felquer ML, Jaihyun Cho R
    IL-23 inhibition for chronic inflammatory disease.
    Lancet. 2024;404:1679-1692.
    PubMed     Abstract available



  8. Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.
    Lancet. 2024;404:1407-1418.
    PubMed     Abstract available


  9. TARANTINO P, Tolaney SM
    Progress in breast cancer management.
    Lancet. 2024;404:1376-1378.
    PubMed    


    September 2024
  10. NARAGHI K, Marzo-Ortega H
    Progressive cervical osteophytosis and dysphagia associated with isotretinoin treatment for rosacea.
    Lancet. 2024;404:e4.
    PubMed    


    August 2024
  11. LEBWOHL MG, Thoma C, Haeufel T
    Spesolimab use in generalised pustular psoriasis flares - Authors' reply.
    Lancet. 2024;404:847-848.
    PubMed    


  12. OSBORNE S, Thacker S, Kam O, Wescott R, et al
    Spesolimab use in generalised pustular psoriasis flares.
    Lancet. 2024;404:846-847.
    PubMed    


  13. MANN GB, Rose AK, Zdenkowski N
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial - Authors' reply.
    Lancet. 2024;404:526.
    PubMed    


  14. KUNKLER I, Cameron D, Dixon M, Williams L, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525.
    PubMed    


  15. SWANICK CW, Kelly P, Dvorak T, Mamounas EP, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525-526.
    PubMed    


  16. MO DC, Huang JF, Luo PH, Wang HL, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:524-525.
    PubMed    


  17. RENERT-YUVAL Y, Guttman-Yassky E
    Hands-on: a novel JAK inhibitor for the treatment of chronic hand eczema.
    Lancet. 2024;404:409-411.
    PubMed    


    July 2024
  18. RUGO HS, Bardia A, Tolaney S
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
    Lancet. 2024;404:339-340.
    PubMed    


  19. HARADA K, Ozaki A, Tanimoto T
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:339.
    PubMed    


  20. MESSORI A
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338-339.
    PubMed    


  21. GU Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338.
    PubMed    


  22. ERGUN Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:337-338.
    PubMed    


  23. ZUBERBIER T, Ensina LF, Gimenez-Arnau A, Grattan C, et al
    Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment.
    Lancet. 2024;404:393-404.
    PubMed     Abstract available


  24. BRUNNER PM
    A novel treatment approach for atopic dermatitis.
    Lancet. 2024 Jul 25:S0140-6736(24)01488-0. doi: 10.1016/S0140-6736(24)01488.
    PubMed    


  25. SILVERBERG JI, Wollenberg A, Reich A, Thaci D, et al
    Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.
    Lancet. 2024 Jul 24:S0140-6736(24)01203-0. doi: 10.1016/S0140-6736(24)01203.
    PubMed     Abstract available


  26. BISSONNETTE R, Warren RB, Pinter A, Agner T, et al
    Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase 3 trials.
    Lancet. 2024 Jul 18:S0140-6736(24)01027-4. doi: 10.1016/S0140-6736(24)01027.
    PubMed     Abstract available


    June 2024
  27. DELALOGE S, Khan SA, Wesseling J, Whelan T, et al
    Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
    Lancet. 2024;403:2734-2746.
    PubMed     Abstract available


  28. MOLINELLI E, Simonetti O
    Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa.
    Lancet. 2024;403:2457-2459.
    PubMed    


    May 2024
  29. BHUTTA MF, Leach AJ, Brennan-Jones CG
    Chronic suppurative otitis media.
    Lancet. 2024;403:2339-2348.
    PubMed     Abstract available


  30. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    PubMed     Abstract available


  31. PRASAD A
    Miriam Mutebi: transforming breast cancer care in Africa.
    Lancet. 2024;403:1975.
    PubMed    


  32. COLES CE, Haviland JS, Kirby AM, Griffin C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
    Lancet. 2024;403:1752.
    PubMed    


  33. GREGUCCI F, Ciabattoni A
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751-1752.
    PubMed    


  34. MULLIEZ T, De Ridder M
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751.
    PubMed    


  35. GUINOT JL, Gutierrez C, Hannoun-Levi JM
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1750-1751.
    PubMed    


  36. MIZUMOTO M, Oshiro Y, Sakurai H
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749-1750.
    PubMed    


  37. ZHAO D, Li Y, Qu Y, He C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749.
    PubMed    


    April 2024
  38. DE SOUZA IC, Langer FW
    Post-radiation angiosarcoma of the breast in a patient with a history of invasive ductal carcinoma.
    Lancet. 2024;403:1681-1682.
    PubMed    


  39. MOODLEY J, Unger-Saldana K
    The role of racial and ethnic discrimination in breast cancer disparities.
    Lancet. 2024 Apr 12:S0140-6736(24)00699-8. doi: 10.1016/S0140-6736(24)00699.
    PubMed    


  40. COLES CE, Earl H, Anderson BO, Barrios CH, et al
    The Lancet Breast Cancer Commission.
    Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747.
    PubMed    


  41. SAMARASEKERA U
    Charlotte Coles: collaborating to tackle breast cancer inequities.
    Lancet. 2024 Apr 12:S0140-6736(24)00752-9. doi: 10.1016/S0140-6736(24)00752.
    PubMed    


  42. EARL HM
    Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
    Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
    PubMed    


  43. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    PubMed     Abstract available


    March 2024
  44. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
    Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
    Lancet. 2024;403:1240.
    PubMed    


  45. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
    Benefits and risks of anthracyclines in early-stage breast cancer.
    Lancet. 2024;403:1239-1240.
    PubMed    


  46. EMMI G, Bettiol A, Hatemi G, Prisco D, et al
    Behcet's syndrome.
    Lancet. 2024;403:1093-1108.
    PubMed     Abstract available


  47. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    PubMed     Abstract available


    February 2024
  48. STONE GW, Christiansen EH, Ali ZA, Andreasen LN, et al
    Intravascular imaging-guided coronary drug-eluting stent implantation: an updated network meta-analysis.
    Lancet. 2024 Feb 21:S0140-6736(23)02454-6. doi: 10.1016/S0140-6736(23)02454.
    PubMed     Abstract available


  49. KRONBICHLER A, Bajema IM, Bruchfeld A, Mastroianni Kirsztajn G, et al
    Diagnosis and management of ANCA-associated vasculitis.
    Lancet. 2024;403:683-698.
    PubMed     Abstract available


  50. KIMBALL AB, Ravichandran S
    Secukinumab treatment of hidradenitis suppurativa: questions remain - Authors' reply.
    Lancet. 2024;403:617-618.
    PubMed    


  51. ENDO M, Kami M
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:617.
    PubMed    


  52. MAUL JT, Kolios AGA, Thomsen SF, Ring HC, et al
    Secukinumab treatment of hidradenitis suppurativa: questions remain.
    Lancet. 2024;403:616-617.
    PubMed    


    January 2024
  53. BAKKER T, Klopotowska JE, Dongelmans DA, Eslami S, et al
    The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial.
    Lancet. 2024 Jan 19:S0140-6736(23)02465-0. doi: 10.1016/S0140-6736(23)02465.
    PubMed     Abstract available


  54. WEBER JS, Carlino MS, Khattak A, Meniawy T, et al
    Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
    Lancet. 2024 Jan 18:S0140-6736(23)02268-7. doi: 10.1016/S0140-6736(23)02268.
    PubMed     Abstract available


  55. MAURER M, Ensina LF, Gimenez-Arnau AM, Sussman G, et al
    Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
    Lancet. 2024;403:147-159.
    PubMed     Abstract available


  56. MOUSSA S, Netchiporouk E
    Comparative efficacy of ligelizumab versus omalizumab in chronic spontaneous urticaria.
    Lancet. 2024;403:118-119.
    PubMed    


    December 2023
  57. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    PubMed     Abstract available


  58. BRAUNSTEIN LZ
    Optimising adjuvant breast radiotherapy via preoperative imaging.
    Lancet. 2023 Dec 5:S0140-6736(23)02698-3. doi: 10.1016/S0140-6736(23)02698.
    PubMed    


  59. MANN GB, Skandarajah AR, Zdenkowski N, Hughes J, et al
    Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study.
    Lancet. 2023 Dec 5:S0140-6736(23)02476-5. doi: 10.1016/S0140-6736(23)02476.
    PubMed     Abstract available


    November 2023
  60. SAKAI K, Miyamori D
    Hyperviscosity syndrome caused by cryoglobulinemia diagnosed by observing the reversible formation of gel upon cooling and warming the patient's serum.
    Lancet. 2023;402:1866.
    PubMed    


  61. DEVJANI S, Engel PV, Javadi SS, Smith B, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis.
    Lancet. 2023;402:1833-1834.
    PubMed    


  62. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply.
    Lancet. 2023;402:1834.
    PubMed    



  63. Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials.
    Lancet. 2023 Nov 3:S0140-6736(23)01082-6. doi: 10.1016/S0140-6736(23)01082.
    PubMed     Abstract available


  64. LEVINE MN
    Effective and safe regional node irradiation in early breast cancer.
    Lancet. 2023 Nov 3:S0140-6736(23)01614-8. doi: 10.1016/S0140-6736(23)01614.
    PubMed    


  65. ZAMAN M, de Vale ML, Coultas C, Goff L, et al
    Factors affecting the delivery of community-based salon interventions to prevent cardiovascular disease and breast cancer among ethnically diverse women in South London: a concept-mapping approach.
    Lancet. 2023;402 Suppl 1:S96.
    PubMed     Abstract available


  66. SINGH M, Wambua S, Lee SI, Okoth K, et al
    Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.
    Lancet. 2023;402 Suppl 1:S84.
    PubMed     Abstract available


  67. HUNTLEY C, Torr B, Sud A, Houlston RS, et al
    The impact of risk stratification by polygenic risk and age on breast cancer screening in women aged 40-49 years: a modelling study.
    Lancet. 2023;402 Suppl 1:S54.
    PubMed     Abstract available


  68. ACHARYA A, Darzi A, Judah G
    An SMS and animated video intervention to increase uptake of breast cancer screening: a randomised controlled trial.
    Lancet. 2023;402 Suppl 1:S17.
    PubMed     Abstract available


    October 2023
  69. ESPIGOL-FRIGOLE G, Dejaco C, Mackie SL, Salvarani C, et al
    Polymyalgia rheumatica.
    Lancet. 2023;402:1459-1472.
    PubMed     Abstract available


    September 2023
  70. HANOUNEH M, Arend LJ
    Ichthyosis in sarcoidosis: a rare skin manifestation of a systemic disease.
    Lancet. 2023;402:1083-1084.
    PubMed    


  71. JO SJ, Jaihyun Cho R
    Preventing generalised pustular psoriasis.
    Lancet. 2023 Sep 19:S0140-6736(23)01480-0. doi: 10.1016/S0140-6736(23)01480.
    PubMed    


  72. MORITA A, Strober B, Burden AD, Choon SE, et al
    Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
    Lancet. 2023 Sep 19:S0140-6736(23)01378-8. doi: 10.1016/S0140-6736(23)01378.
    PubMed     Abstract available


  73. BECKER JC, Ugurel S, Leiter U, Meier F, et al
    Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
    Lancet. 2023;402:798-808.
    PubMed     Abstract available


  74. SAIAG P, Blom A
    Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
    Lancet. 2023;402:751-753.
    PubMed    


  75. MANSFIELD BS, Raal FJ
    Regression of cutaneous xanthomata in patient with homozygous familial hypercholesterolemia using novel therapies.
    Lancet. 2023;402:e11.
    PubMed    


    August 2023
  76. RUGO HS, Bardia A, Marme F, Cortes J, et al
    Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Aug 23:S0140-6736(23)01245-X. doi: 10.1016/S0140-6736(23)01245.
    PubMed     Abstract available


  77. THORNTON J
    Scabies in Cox's Bazar.
    Lancet. 2023;402:600.
    PubMed    


    July 2023
  78. LONG GV, Swetter SM, Menzies AM, Gershenwald JE, et al
    Cutaneous melanoma.
    Lancet. 2023 Jul 24:S0140-6736(23)00821-8. doi: 10.1016/S0140-6736(23)00821.
    PubMed     Abstract available


    June 2023
  79. COLES CE, Haviland JS, Kirby AM, Griffin CL, et al
    Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
    Lancet. 2023 Jun 8:S0140-6736(23)00619-0. doi: 10.1016/S0140-6736(23)00619.
    PubMed     Abstract available


    April 2023
  80. IQBAL M, Kharfan-Dabaja MA
    Cogent data on allogeneic haematopoietic stem-cell transplantation efficacy in advanced cutaneous T-cell lymphoma.
    Lancet. 2023 Apr 24:S0140-6736(23)00631-1. doi: 10.1016/S0140-6736(23)00631.
    PubMed    


  81. DE MASSON A, Beylot-Barry M, Ram-Wolff C, Mear JB, et al
    Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
    Lancet. 2023 Apr 24:S0140-6736(23)00329-X. doi: 10.1016/S0140-6736(23)00329.
    PubMed     Abstract available


  82. HAKIMI M, North JP, Taylor MA, Hailer A, et al
    Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease.
    Lancet. 2023;401:1381.
    PubMed    


  83. ANDRE F, Hee Park Y, Kim SB, Takano T, et al
    Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Apr 19:S0140-6736(23)00725-0. doi: 10.1016/S0140-6736(23)00725.
    PubMed     Abstract available


  84. CHUMSRI S
    Advancing outcomes of metastatic HER2-positive breast cancer.
    Lancet. 2023 Apr 19:S0140-6736(23)00805-X. doi: 10.1016/S0140-6736(23)00805.
    PubMed    



  85. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
    Lancet. 2023;401:1277-1292.
    PubMed     Abstract available


  86. SHEN SJ, Liu CM
    Chemotherapy for early-stage breast cancer: the more the better?
    Lancet. 2023;401:1243-1245.
    PubMed    


  87. MULLER M, Ingold-Heppner B, Stocker H, Heppner FL, et al
    Skin lesion specimens as first choice to detect monkeypox virus - Authors' reply.
    Lancet. 2023;401:1265.
    PubMed    


  88. ZHOU YB
    Skin lesion specimens as first choice to detect monkeypox virus.
    Lancet. 2023;401:1264-1265.
    PubMed    


  89. KING B, Zhang X, Harcha WG, Szepietowski JC, et al
    Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
    Lancet. 2023 Apr 13:S0140-6736(23)00222-2. doi: 10.1016/S0140-6736(23)00222.
    PubMed     Abstract available


  90. JAVAUD N, Gobert D
    Hereditary angioedema: is there a better future for treatment?
    Lancet. 2023;401:1054-1055.
    PubMed    


  91. CRAIG TJ, Reshef A, Li HH, Jacobs JS, et al
    Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023;401:1079-1090.
    PubMed     Abstract available


    March 2023
  92. EGEBERG A, Thyssen JP
    The optimal biologic treatment target for hidradenitis suppurativa remains undiscovered.
    Lancet. 2023;401:708-710.
    PubMed    


  93. KIMBALL AB, Jemec GBE, Alavi A, Reguiai Z, et al
    Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
    Lancet. 2023;401:747-761.
    PubMed     Abstract available


    February 2023
  94. CORREA-SELM L, Hanlon KL, Grichnik JM
    Differentiating activated Langerhans cells and dendritic melanocytes using reflectance confocal microscopy: the limitations of diagnosing melanoma in vivo.
    Lancet. 2023;401:590.
    PubMed    


  95. AYGOREN-PURSUN E, Zanichelli A, Cohn DM, Cancian M, et al
    An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial.
    Lancet. 2023;401:458-469.
    PubMed     Abstract available


  96. RESHEF A, Grumach AS
    New medications to mitigate attacks of hereditary angioedema: does one size fit all?
    Lancet. 2023;401:413-415.
    PubMed    


    January 2023
  97. VOLKMANN ER, Andreasson K, Smith V
    Systemic sclerosis.
    Lancet. 2023;401:304-318.
    PubMed     Abstract available


  98. ZHOU YB
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed.
    Lancet. 2023;401:104.
    PubMed    


  99. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Pseudovesicular appearance in Sweet's syndrome: important yet easily missed - Authors' reply.
    Lancet. 2023;401:104.
    PubMed    


  100. CHUA BH, Link EK, Kunkler IH, Olivotto IA, et al
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost? - Authors' reply.
    Lancet. 2023;401:24.
    PubMed    


  101. MULLIEZ T, De Ridder M
    Breast radiotherapy for non-low-risk ductal carcinoma in situ: to boost or not to boost?
    Lancet. 2023;401:23-24.
    PubMed    


  102. MEROLA JF, Landewe R, McInnes IB, Mease PJ, et al
    Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
    Lancet. 2023;401:38-48.
    PubMed     Abstract available


  103. QUEIRO R
    Bimekizumab in psoriatic arthritis: a great leap forward?
    Lancet. 2023;401:2-3.
    PubMed    


  104. MCINNES IB, Asahina A, Coates LC, Landewe R, et al
    Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
    Lancet. 2023;401:25-37.
    PubMed     Abstract available


  105. MITJA O, Ogoina D, Titanji BK, Galvan C, et al
    Monkeypox.
    Lancet. 2023;401:60-74.
    PubMed     Abstract available


    December 2022
  106. THYSSEN JP, Schmid-Grendelmeier P
    Long-term disease control in atopic dermatitis using biologics.
    Lancet. 2022 Dec 9:S0140-6736(22)02347-9. doi: 10.1016/S0140-6736(22)02347.
    PubMed    


  107. GUTTMAN-YASSKY E, Simpson EL, Reich K, Kabashima K, et al
    An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
    Lancet. 2022 Dec 9:S0140-6736(22)02037-2. doi: 10.1016/S0140-6736(22)02037.
    PubMed     Abstract available


  108. RASSY E, Delaloge S
    A second-generation antibody-drug conjugate to treat HER2-positive breast cancer.
    Lancet. 2022 Dec 7:S0140-6736(22)02534-X. doi: 10.1016/S0140-6736(22)02534.
    PubMed    


  109. HURVITZ SA, Hegg R, Chung WP, Im SA, et al
    Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial.
    Lancet. 2022 Dec 6:S0140-6736(22)02420-5. doi: 10.1016/S0140-6736(22)02420.
    PubMed     Abstract available


    November 2022
  110. SANCHEZ-MEZA E, Kubelis-Lopez DE, Ocampo-Candiani J, Chavez-Alvarez S, et al
    Prominent skin folds of the scalp provide a superficial clue in acromegaly.
    Lancet. 2022;400:1802.
    PubMed    


  111. VRSELJA A, Latifi A, Baber RJ, Stuckey BGA, et al
    Q-122 as a novel, non-hormonal, oral treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2022;400:1704-1711.
    PubMed     Abstract available


  112. CRANDALL CJ, Ganz PA
    Phase 2 data on a new treatment for hot flushes in women with breast cancer.
    Lancet. 2022;400:1659-1661.
    PubMed    


    October 2022

  113. Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial.
    Lancet. 2022;400:1334-1344.
    PubMed     Abstract available


    September 2022
  114. KIM S, Wuthrick E, Blakaj D, Eroglu Z, et al
    Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
    Lancet. 2022;400:1008-1019.
    PubMed     Abstract available


  115. SAIAG P, Blom A
    Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma.
    Lancet. 2022;400:976-977.
    PubMed    


  116. PALLER AS, Simpson EL, Siegfried EC, Cork MJ, et al
    Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2022;400:908-919.
    PubMed     Abstract available


  117. HALLING AS, Thyssen JP
    Biological therapy for young children with atopic dermatitis.
    Lancet. 2022;400:867-869.
    PubMed    


  118. LIVINGSTONE E, Zimmer L, Hassel JC, Fluck M, et al
    Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01654.
    PubMed     Abstract available


  119. SMITHY JW, Postow MA
    Adjuvant checkpoint blockade following complete local therapy for melanoma metastases.
    Lancet. 2022 Sep 9. pii: S0140-6736(22)01748.
    PubMed    


    August 2022
  120. DESCAMPS V
    DRESS syndrome.
    Lancet. 2022;400:560.
    PubMed    


  121. HINDIE E
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed?
    Lancet. 2022;400:559.
    PubMed    


  122. LUKE JJ, Ibrahim N, Eggermont AM
    Adjuvant therapy in stage IIB and IIC melanoma: is sentinel biopsy needed? - Authors' reply.
    Lancet. 2022;400:559-560.
    PubMed    


  123. CHUA BH, Link EK, Kunkler IH, Whelan TJ, et al
    Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
    Lancet. 2022;400:431-440.
    PubMed     Abstract available


  124. COLES CE, Chatterjee S, Jagsi R, Kirby AM, et al
    Breast radiotherapy for ductal carcinoma in situ: could less be more?
    Lancet. 2022;400:408-410.
    PubMed    


    July 2022
  125. REICH K, Thyssen JP, Blauvelt A, Eyerich K, et al
    Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Lancet. 2022;400:273-282.
    PubMed     Abstract available


  126. MENNINI M, Di Nardo G, Fiocchi AG
    Atopic dermatitis: time for tailored therapy.
    Lancet. 2022;400:252-253.
    PubMed    


  127. RUDD EC, Kulasekararaj A, Basu TN
    Facial lymphoedema, viral warts, and myelodysplastic syndrome: the protean condition of GATA2 deficiency.
    Lancet. 2022;400:236.
    PubMed    


    June 2022
  128. SKJERVEN HO, Lie A, Vettukattil R, Rehbinder EM, et al
    Early food intervention and skin emollients to prevent food allergy in young children (PreventADALL): a factorial, multicentre, cluster-randomised trial.
    Lancet. 2022;399:2398-2411.
    PubMed     Abstract available


  129. BANARES J, Aceituno L, Jimenez A, Maynard A, et al
    Sweet's syndrome and Crohn's disease diagnosed simultaneously.
    Lancet. 2022;399:2155.
    PubMed    


    May 2022
  130. HIBI T
    Risankizumab for Crohn's disease.
    Lancet. 2022;399:1992-1993.
    PubMed    


  131. DANESE S, Vermeire S, Zhou W, Pangan AL, et al
    Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
    Lancet. 2022 May 26. pii: S0140-6736(22)00581.
    PubMed     Abstract available


  132. ABDELNABI M, Elmssary M, Sekhon J, Benjanuwattra J, et al
    Acute onset of fever, eosinophilia, rash, acute kidney injury, and a positive Monospot test in a patient on lamotrigine: DRESS syndrome.
    Lancet. 2022;399:1902.
    PubMed    


    April 2022
  133. MEGALY M, Boshra N
    Pyogenic granuloma-like Kaposi's sarcoma.
    Lancet. 2022;399:e38.
    PubMed    


  134. TCHERNEV G, Chokoeva AA
    Melanoma in a Chinese dragon tattoo.
    Lancet. 2022;399:e37.
    PubMed    


    March 2022
  135. LUKE JJ, Rutkowski P, Queirolo P, Del Vecchio M, et al
    Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
    Lancet. 2022 Mar 31. pii: S0140-6736(22)00562.
    PubMed     Abstract available


  136. DRIVENES JL, Betz RC, Bygum A
    A girl with unruly locks: molecular genetics makes a diagnosis of uncombable hair syndrome.
    Lancet. 2022;399:1079.
    PubMed    


  137. CRAIG T, Magerl M, Levy DS, Reshef A, et al
    Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet. 2022;399:945-955.
    PubMed     Abstract available


  138. FIJEN LM, Levi M
    Prophylaxis with anti-activated factor XII for hereditary angioedema.
    Lancet. 2022;399:889-890.
    PubMed    


    February 2022
  139. KUMAR A, Preston N, Phillips R
    Picturing health: Buruli ulcer in Ghana.
    Lancet. 2022;399:786-797.
    PubMed    


  140. COLES CE, Anderson BO, Cameron D, Cardoso F, et al
    The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge.
    Lancet. 2022 Feb 18. pii: S0140-6736(22)00184.
    PubMed    


    December 2021
  141. AL-MATAR SH, Sairam C, Roussel L, Langelier MJ, et al
    Fever, abdominal pain, serositis, arthralgia, hearing loss, proteinuria, and a family history: Muckle Wells syndrome.
    Lancet. 2021;398:2101.
    PubMed    


    November 2021
  142. MURPHY MJ, Damsky W, Vesely MD
    A pruritic psoriatic plaque develops at the donor site of an autologous skin graft: Koebner phenomenon.
    Lancet. 2021;398:1836.
    PubMed    


    October 2021
  143. GONZALES E, Hardikar W, Stormon M, Baker A, et al
    Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Lancet. 2021;398:1581-1592.
    PubMed     Abstract available


    April 2021
  144. LOIBL S, Poortmans P, Morrow M, Denkert C, et al
    Breast cancer.
    Lancet. 2021 Apr 1. pii: S0140-6736(20)32381.
    PubMed     Abstract available


    March 2021
  145. WANG C, Li A, Shi Q, Yu Z, et al
    Metagenomic next-generation sequencing clinches diagnosis of leishmaniasis.
    Lancet. 2021;397:1213.
    PubMed    


    January 2021

  146. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.
    Lancet. 2021;397:387-397.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.